Infusion and injection-related reactions, along with respiratory and urinary tract infections, emerged as the most reported adverse events in people with MS (pwMS) participating in anti-CD20 MS clinical trials (5, 12). This evidence concerns the gene MS4A1 and myeloid sarcoma.